Acceptance of tamoxifen chemoprevention by physicians and women at riskTCHOU, Julia; NANJIANG HOU; RADEMAKER, Alfred et al.Cancer. 2004, Vol 100, Num 9, pp 1800-1806, issn 0008-543X, 7 p.Article

Characteristics of salivary profiles of oestradiol and progesterone in premenopausal womenCHATTERTON, Robert T; MATEO, Esnar T; NANJIANG HOU et al.Journal of endocrinology. 2005, Vol 186, Num 1, pp 77-84, issn 0022-0795, 8 p.Article

A prospective study of variability in mammographic density during the menstrual cycleMORROW, Monica; CHATTERTON, Robert T; RADEMAKER, Alfred W et al.Breast cancer research and treatment. 2010, Vol 121, Num 3, pp 565-574, issn 0167-6806, 10 p.Article

TGFBR1*6A and cancer risk: A meta-analysis of seven case-control studiesKAKLAMANI, Virginia G; NANJIANG HOU; YIANSONG BIAN et al.Journal of clinical oncology. 2003, Vol 21, Num 17, pp 3236-3243, issn 0732-183X, 8 p.Article

G-CSF is not necessary to maintain over 99% dose-intensity with ABVD in the treatment of hodgkin lymphoma: low toxicity and excellent outcomes in a 10-year analysisEVENS, Andrew M; CILLEY, Jeffrey; TALLMAN, Martin S et al.British journal of haematology. 2007, Vol 137, Num 6, pp 545-552, issn 0007-1048, 8 p.Article